The global stem cells market size was estimated at USD 6.87 billion in 2016. Despite their usage being slightly controversial, they have gained significant attention from multidisciplinary community of scientists. Factors that have influenced the growth of this market are huge success of regenerative medicine as well as exponential growth in ongoing SC-based research.
SCs are observed to aptly serve the community engaged in disease management by revealing new aspects of disease treatment. These cells have created immense opportunities for development of cellular models to provide better picture of disease mechanism.
UK stem cells market share, by technology, 2014 - 2025 (USD Million)
Breakthrough innovations brought about in this field include limitless supply of induced pluripotent stem cells (iPSCs) and endeavors for regeneration of dying or diseased cells and tissues. Such advancements enable researchers to generate PSCs from adult somatic cells which further helps in preserving genetic information within these cells.
Ongoing R&D into SCs has revolutionized the “clinical trial in a dish” in areas that are dominated with personalized medicine approach. In addition, entities are entering in strategic partnership to investigate the publication trends in this arena.
Several studies have been carried out to assess the trend in stem cell culture. These studies are anticipated to help companies in bringing potential qualitative and quantitative changes in product line. Understanding their role, funding bodies continue to increase their investment for accelerating SC research.
However, ethical concerns coupled with public perception in context to SCs research at different phases of research is anticipated to impede the implementation of this therapy up to certain extent.
Adult stem cells are estimated to account for largest revenue share in 2016. Low contamination probability while sub-culturing and expansion-high compatibility with human body, and less production labor associated with it are the factors responsible for the share.
As IPSCs provide a window into human development owing to the breakthrough advances, these cells are expected to grow at a fastest rate in the coming years. Ongoing research with respect to drug screening and organoid generation are the key drivers for this segment.
Regenerative medicine is observed to hold the potential for devising early-intervention treatments to cure degenerative diseases and traumatic injury. Furthermore, this availability of the methodology across wide range of clinical areas is driving the segment growth.
Neurology accounted for the largest revenue share in regenerative medicine owing to the presence of significant FDA approved products. However, strong pipeline portfolio for cancer therapies is anticipated to boost growth in oncology renewing medicine.
SCs are recognized to create new opportunities for pharmaceutical companies by advancing the identification of lead candidates and enabling firms to develop novel drugs. Moreover, SC-based researches have advanced single-cell analysis which further helps in studying drug effects on cell differentiation. In addition, growing reliance of drug developing entities on cellular systems is anticipated to help this segment in gaining ground in future market.
Being a basic step, cell acquisition technology is estimated to account for the largest share and is expected to maintain this position throughout the forecast period. Growing awareness about their significance has led to significant growth in cell harvesting, which in turn, has contributed to its large share.
Bone marrow is the most used technology for cell acquisition owing to the fact that production of new cells from bone marrow stem cells is relatively faster. Moreover, bone marrow originated cells are comparatively more concentrated than from other sites.
Cell production technology accounted for the significant share owing to the ongoing advancements in the technology. These advancements are aimed at fulfilling the growing need of SCs for various clinical applications.
On the basis of steps, technology for cell production is segregated into therapeutic cloning, in-vitro fertilization, culturing, and isolation technologies. Growing organ replacement and significance of therapeutic cloning in advancing the organ replacement has spurred progress of this segment
Autologous stem cell therapy dominated the market with respect to revenue generation in 2016, as a consequence of the higher uptake of these products. The factors responsible for the higher uptake are higher compatibility associated with them.
Although the marketplace is unregulated and includes scrutiny from several government bodies, there are several companies engaged in development of autologous SC products for patients with sports injuries. Aforementioned fact remains crucial for the revenue generated in this segment.
Rise in the number of R&D projects carried out in the Japan, Australia, and Singapore, is anticipated to drive progress in this region lucratively. Asian countries are projected to be the leaders in fast-growing stem cell field with changes in the regulatory policies in the developing economies of this region. Accelerated commercialization opportunities in Asian countries is anticipated to drive market forward.
Global stem cell market, by region, 2016 (%)
Significant investment from government and private sector is anticipated to drive growth in this market. Presence of well-defined business models in the U.S. and Canada, is progressing the market growth in this region. Meanwhile, regulatory changes with respect to regenerative medicine in Japan has attracted significant interest in Japanese market, especially due to accelerated commercialization opportunities.
Some of the key participants in the space include STEMCELL Technologies Inc., Osiris Therapeutics Inc, Celgene Corporation, BIOTIME, INC., Cynata, Human Longevity Inc, Advanced Cell Technology Inc, Cytori Therapeutics, Mesoblast, and Promethera Biosciences
Companies are engaged in expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. Presence of wide product portfolio is anticipated to drive competition in the market, consequently leading to growth
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Billion and CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, Germany, UK, China, Japan, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global stem cells market on the basis of product, application, technology, therapy, and region:
Product Outlook (Revenue, USD Billion, 2014 - 2025)
Adult Stem Cells
Neuronal Stem Cells
Hematopoietic Stem Cells
Mesenchymal Stem Cells
Umbilical Cord Stem Cells
Human Embryonic Stem Cells
Induced Pluripotent Stem Cells
Very Small Embryonic Like Stem Cells
Application Outlook (Revenue, USD Billion, 2014 - 2025)
Cardiovascular and Myocardial Infraction
Drug Discovery and Development
Technology Outlook (Revenue, USD Billion, 2014 - 2025)
Bone Marrow Harvest
Umbilical Blood Cord
Expansion and Sub-Culture
Therapy Outlook (Revenue, USD Billion, 2014 - 2025)
Autologous Stem Cell Therapy
Allogeneic Stem Cell Therapy
Regional Outlook (Revenue, USD Billion, 2014 - 2025)
Middle East & Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."